Evicenter
Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer
Manufacturer
Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP
Prescribing information
Enhertu (opens in a new tab)
Questions
30
Last updated

All questions

Dosing and administration: Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer

1 question · 2 sources